Abivax and Newron Pharmaceuticals report H1 2026 financial results

Biopharmaceutical companies Abivax and Newron Pharmaceuticals have released their first-half 2026 financial results, highlighting both clinical progress and financial shifts.

Abivax reported a widening net loss of €165.9 million for the first half of 2026, driven by increased research and development costs for its lead candidate, obefazimod. Despite the loss, the company significantly strengthened its liquidity through a July public offering, providing a cash runway into the fourth quarter of 2029. Abivax also announced leadership changes, appointing Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer to prepare for potential commercialization.

Newron Pharmaceuticals reported a net loss of €16.4 million for the first half of 2026, as research and development expenses for its schizophrenia candidate, evenamide, more than doubled. The company noted progress in its Phase 3 ENIGMA-TRS 1 program, with topline 12-week results expected in Q1 2027. Newron also secured a financing agreement for up to €38 million and received a €5.5 million milestone payment from partner EA Pharma.